Abstracts Archive - Page 123 of 2607 - ACR Meeting Abstracts

Abstract Number: 1563 • ACR Convergence 2025
RESET-SSc: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Systemic Sclerosis
Dinesh Khanna¹, Monalisa Ghosh¹, Ankoor Shah², Sonali Bracken³, george georges⁴, Carrie Richardson⁵, Pei-Suen Tsou¹, Charles Ross⁶, Carleigh Zahn¹, Courtney Little⁷, Carl diCasoli⁷, Mikaela Raymond⁷, Adreeja GuhaRay⁷, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Domenick Braccia⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹University of Michigan, Ann Arbor, MI, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁴Northwestern Medicine, Evanston, IL, ⁵Northwestern University, Chicago, IL, ⁶University of Michigan, Ann Arbor, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The treatment goals for systemic sclerosis (SSc) are to control disease activity, limit progression of organ damage and decrease long-term morbidity and mortality. Therapies…
Abstract Number: 1650 • ACR Convergence 2025
Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction
Hannah Johnson¹, Wenxian Zhou², Michael Duryee¹, Engle Sharp¹, Kimberley Sinanan¹, Carlos Hunter¹, Tate Johnson¹, Mabruka Alfaidi¹, Daniel Anderson³, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ^30587964, Durham, NC
Background/Purpose: Previous reports show that malondialdehyde-acetaldehyde (MAA) adducts are overexpressed in RA, especially in joint/lung tissues, and that they colocalize with citrulline (CIT). This is…
Abstract Number: 1627 • ACR Convergence 2025
A systematic literature review to inform the 2025 EULAR recommendations for management of Polymyalgia Rheumatica and Large Vessel Vasculitis: management of disease including relapse and complications
Mrinalini Dey¹, Durga Prasanna Misra², Alice Bartoletti³, Georgina Ducker⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ³ASST Gaetano Pini CTO, Cremona, Italy, ⁴Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: EULAR recommendations informing the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) were previously published separately in 2015 [1] and 2020 [2]…
Abstract Number: 1655 • ACR Convergence 2025
Aberrant Noncoding RNAs Are Enriched in Extracellular Vesicles and Implicated in Interferon Activation
Sandra Williams¹, Soyeong Sim² and Sandra Wolin², ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases; National Cancer Institute, Bethesda, MD, ²National Cancer Institute, Frederick, MD
Background/Purpose: Extracellular vesicles (EVs) are small structures that enclose a variety of nucleic acids. While much of the published work on EV RNA has focused…
Abstract Number: 1676 • ACR Convergence 2025
Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study
Roy Fleischmann¹, Jerzy Swierkot², Patrick Durez³, Louis Bessette⁴, Xianwei Bu⁵, Irina Fish⁵, Andrew Gara⁵, Diane Caballero⁵, Charles Peterfy, MD, PhD⁶, Yoshiya Tanaka⁷ and Eduardo Mysler⁵, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Wroclaw Medical University, Department of Rheumatology and Internal Medicine, Wroclaw, Poland, ³Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ⁴Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁵AbbVie Inc., North Chicago, ⁶Spire Sciences, Inc., Boca Raton, FL, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: We assessed the safety and efficacy of UPA versus ADA from SELECT-COMPARE through 7-years.Methods: Patients with RA and an inadequate response to MTX were…
Abstract Number: 1625 • ACR Convergence 2025
Factor VIII as a Potential Biomarker of Disease Activity in Relapsing Polychondritis
Ashika Ajitumar¹, Eric Robbins², Yusuf Mastoor² and Marcela ferrada³, ¹University of Maryland, baltimore, MD, ²University of Maryland, baltimore, ³University of Maryland, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare autoimmune disease marked by episodic inflammation of cartilaginous tissues. A major challenge in its clinical management is the…
Abstract Number: 1569 • ACR Convergence 2025
Can We Use Patient Reported Outcomes For Home-monitoring in SSc?
Eva Hoekstra¹, Katherine van der Wouden², Queeny Madari¹, Saad Ahmed³, Lianne Kwant¹, Ada Hortensius-Varkevisser¹, Emiel Marges¹, Jacopo Ciaffi⁴, Anne Schouffoer⁵, Tom Huizinga⁶ and Jeska de Vries-Bouwstra⁶, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center and Amsterdam University Medical Center, Leiden, Zuid-Holland, Netherlands, ³LUMC, Leiden, Netherlands, ⁴IRCCS Istituto Ortopedico Rizzoli, Bologna, Bologna, Italy, ⁵HagaZiekenhuis the Hague, the Hague, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Home-monitoring is a suitable strategy to reduce the frequency of hospital visits, and alleviate strain on healthcare resources. However, in systemic sclerosis (SSc) this…
Abstract Number: 1670 • ACR Convergence 2025
Large Retrospective Cohort Study Of Chronic Recurrent Multifocal Osteomyelitis: Disease Presentation, Clinical, And Laboratory Features
Shima Yasin¹, Shima Yasin² and Polly Ferguson³, ¹King Abdullah Specialized Children’s Hospital,Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia, ²Univeristy of Iowa, Iowa City, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease that affects children and adolescents. The disease typically presents with bone pain with or…
Abstract Number: 1672 • ACR Convergence 2025
Classification criteria, disease phenotypes and long-term outcomes of childhood Sjögren’s Disease into adulthood
Coziana Ciurtin¹, Ruby Gotch², Hannah Peckham¹, Robert Wilson², Muthana AlObaidi³ and Elizabeth C Jury¹, ¹University College London, London, United Kingdom, ²University College London Hospital NHS Trust, London, United Kingdom, ³Great Ormond Street Hospital, London, United Kingdom
Background/Purpose: Childhood Sjögren Disease (cSjD) is a rare clinical phenotype lacking research on long-term outcomes and impact on the quality of life of young people…
Abstract Number: 1668 • ACR Convergence 2025
A clinically validated assay for rapid determination of type I and type II interferon activity in pediatric inflammatory diseases
Evan Hsu¹, Courtney Leson², Amrita Basu³, Michael Lam⁴, Jian Yue⁴, Casey Rimland⁵, Rachel Weng⁴, Lauren Henderson⁶, Joyce Chang², Mary Beth Son⁴, Fatma Dedeoglu⁴, roshini Abraham³ and Pui Lee¹, ¹Boston Children's Hospital, Newton, MA, ²Boston Children's Hospital, Boston, ³Nationwide Children's Hospital, Columbus, OH, ⁴Boston Children's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, ⁶Boston Children's Hospital, Watertown, MA
Background/Purpose: Type I interferons (IFN-I) and type II interferon (IFN-g) are essential to host defense but dysregulated production of these cytokines is increasingly recognized in…
Abstract Number: 1508 • ACR Convergence 2025
Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Sheila Serin¹, Megan Schluentz¹, Chandana Keshavamurthy¹, Alexandra Reese¹, Sneha Centala¹, Bettina Boone¹, Samantha Ahrens², William Davis³, Robert Quinet¹, Jerald Zakem⁴, Samina Hayat⁵, Sarwat Umer⁶, Teresa leeth⁷, Daniyal Nadeem⁷ and Xin Zhang⁸, ¹Department of Rheumatology, Ochsner Health, New Orleans, LA, ²Multi-specialty Clinical Research, Ochsner Health, New Orleans, LA, ³Ochsner Health System, New Orleans, LA, ⁴Ochsner Health Systems, Metairie, LA, ⁵Louisiana state university Shreveport, Shreveport, LA, ⁶LSUHSC Shreveport, Shreveport, LA, ⁷Louisiana State University Health Science, Shreveport, LA, ⁸Ochsner Medical Center, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation, autoantibody production, and multiorgan involvement. Although genetic, hormonal, and environmental factors…
Abstract Number: 1579 • ACR Convergence 2025
Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Maria Iacovantuono¹, Nicholas landini², lisa Jungblut³, Florian Käs⁴, Rucsandra Dobrota⁵, Sinziana Muraru⁶, Carina Mihai⁷, Muriel Elhai⁸, Mike Becker⁹, Maria Sole Chimenti¹⁰, Thomas Frauenfelder³, Anna-Maria Hoffmann-Vold¹¹, Oliver Distler¹² and Cosimo Bruni¹³, ¹Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, ²Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ³Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁷University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁹Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc). Among radiomics features, the automated quantification of pulmonary vascular volume…
Abstract Number: 1520 • ACR Convergence 2025
Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Bahtiyar Toz¹, Himanshu Vashistha² and Richard Furie³, ¹Zucker School of Medicine at Hofstra/ Northwell, Queens, NY, ²Northwell Health, Great Neck, NY, ³Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Biologic treatments for lupus nephritis (LN) have improved short-term outcomes. Obinutuzumab (OBI), an anti-CD20 monoclonal antibody, demonstrated efficacy in the NOBILITY and REGENCY trials;…
Abstract Number: 1688 • ACR Convergence 2025
Impact of Stress, Anxiety, and Depression on Fatigue as moderated by Resilience and Exposure to Trauma in Rheumatology Patients
Akhila Veeravalli¹, Sankeerthana gajjala² and Sarath Chandra Mouli Veeravalli³, ¹Department of Rheumatology, KIMS Hospitals, Secuderabad, India, Hyderabad, Telangana, India, ²KIMS Hospitals, Secunderabad, India, Hyderabad, Telangana, India, ³Dept. of Rheumatology and Clinical Immunology, KIMS Hospitals, Secunderabad, India, Hyderabad, Telangana, India
Background/Purpose: This study aimed to examine the impact of psychological distress—specifically stress, anxiety, and depression—on fatigue in rheumatology patients, and explored how this relationship is…
Abstract Number: 1678 • ACR Convergence 2025
Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
Andrew Cope¹, Joana Vasconcelos¹, Marianna Jasenecova², Andrew Filer³, Karim Raza⁴, Sumera Qureshi¹, Maria Antonietta D'Agostino⁵, Iain McInnes⁶, Stefan Siebert⁶, John Isaacs⁷, Arthur Pratt⁸, Benjamin A. Fisher⁹, Christopher Buckley¹⁰, Paul Emery¹¹, Kulveer Mankia¹¹, Pauline Ho¹², MAYA BUCH¹³, Coziana Ciurtin¹⁴, Dirkjan van Schaardenburg¹⁵, Tom Huizinga¹⁶, René Toes¹⁶, Caroline Murphy¹ and A. Toby Prevost¹, ¹King's College London, London, United Kingdom, ²King's College London, London, ³The University of Birmingham, Birmingham, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷Newcastle University, Newcastle upon Tyne, United Kingdom, ⁸University of Newcastle, Newcastle, United Kingdom, ⁹King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²The Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom, ¹³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹⁴University College London, London, ¹⁵Amsterdam UMC, Amsterdam, Netherlands, ¹⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Clinical trials aimed at delaying or preventing rheumatoid arthritis (RA) in individuals at risk have been published with variable results. In the APIPPRA study,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].